Table 2.
Strategy rankings—all referencing common baseline (in US$ 2020).
| Strategy | Cost | Incremental cost | QALY | Incremental QALY | ICER | C/E |
|---|---|---|---|---|---|---|
| Diaskintest | 884.70 | 8.386 | 105.50 | |||
| EC skin test | 886.60 | 1.90 | 8.386 | 0 | (Undefined) | 105.73 |
| QFT-Plus | 902.10 | 17.40 | 8.385 | − 0.00055 | − 31,415.80 | 107.59 |
| TST PPD RT 23 | 925.50 | 40.80 | 8.356 | − 0.02967 | − 1,375.09 | 110.76 |
QALY quality-adjusted life year, ICER incremental cost-effectiveness ratio, QFT-Plus QuantiFERON TB Gold Plus, TST tuberculin skin test, PPD RT 23 purified protein derivative, C/E cost effectiveness, US$ US dollars.